Angiotensinogen is shown to be produced by the liver and the hepatoma cell line HepG2. As a first step for understanding the molecular relationship between the transcriptional regulation of the angiotensinogen gene and the pathogenesis of hypertension, we have analyzed the basal promoter of the angiotensinogen gene. Chloramphenicol acetyltransferase (CAT) assays with 5'-deleted constructs showed that the proximal promoter region from -96 to +22 of the transcriptional start site was enough to express HepG2-specific CAT activity. Electrophoretic mobility shift assay and DNase I footprinting demonstrated that the liver-and HepG2-specific nuclear factor (angiotensinogen gene-activating factor IAGF2I) and ubiquitous nuclear factor (AGF3) bound to the proximal promoter element from -96 to -52 (angiotensinogen gene-activating element IAGE2I) and to the core promoter element from -6 to +22 (AGE3), respectively. The site-directed disruption of either AGE2 or AGE3 decreased CAT expression, and the sequential titration of AGF3 binding by in vivo competition remarkably suppressed HepG2-specific CAT activity. Finally, the heterologous thymidine kinase promoter assay showed that AGE2 and AGE3 synergistically conferred HepG2-specific CAT expression. These results suggest that the synergistic interplay between AGF2 and AGF3 is important for the angiotensinogen promoter activation. (J. Clin. Invest. 1994.
Introduction
Hypertension is a complex pathological state with a predisposed genetic background involving the autonomic nervous system and the various hormonal vasoactive peptides. Although a large number of important regulatory genes on the circulation systems had been identified, little information was available on their roles in the development ofhypertension. By contrast, recent studies have demonstrated that the renin-angiotensin system (RAS)' plays an important role in the regula-vating element; AGF, angiotensinogen gene-activating factor; CAT, chloramphenicol acetyltransferase; EMSA, electrophoretic mobility tion ofblood pressure, fluid volume balance, and other biological responses through generation ofangiotensin II, which has a variety of actions such as vasoconstrictor activity and stimulation of the production and release ofaldosterone ( 1 ) . The participation of RAS in several disease states including hypertension has now been proposed (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) .
Angiotensinogen is the unique substrate of renin in RAS, and the primary source of plasma angiotensinogen is the liver ( 16, 17) . We previously demonstrated that the 5'-flanking region of the human angiotensinogen gene was important for tissue-and cell type-specific expression of the gene in vitro ( 18) and in vivo ( 19) . We also disclosed that the promoter region of the mouse angiotensinogen gene was able to direct transcription in HepG2 cells (20) , and other investigators showed that the 750-bp promoter element from the immediate 5'-flanking region was capable of directing most, but not all, tissue-specific and hormonal regulation ofthe angiotensinogen minigene in transgenic mice (21) . Moreover, we have recently indicated that the proximal promoter region is involved in the adipogenic differentiation-induced expression of the angiotensinogen gene (22) . All of these studies indicated that the 5'-flanking sequences played a major role in the regulation ofthe angiotensinogen gene expression.
The synthesis and release ofangiotensinogen into the circulation is regulated in response to a number of different stimuli such as steroid hormones (23) (24) (25) (26) (27) , cytokines (28) , and angiotensin II (29, 30) in the liver. For example, recent studies on the regulation of the gene in the liver during the acute phase response led to the identification of a hormonally induced enhancer unit consisting of two glucocorticoid responsive elements and a cytokine responsive element in the far upstream 5'-flanking region (31, 32) , although the exact role ofangiotensinogen in inflammation is uncertain (33) .
On the other hand, recent transgenic studies using the rat and human angiotensinogen genes (34) (35) (36) (37) and genetic linkage analyses of the human angiotensinogen gene with high blood pressure (38, 39) propose that the basal transcriptional mechanism ofthe angiotensinogen gene is involved in the pathogenesis of hypertension. At present, little information is available concerning the basal transcriptional machinery of the angiotensinogen gene, and the molecular relationship between the regulation of transcription of the gene and the pathogenesis of hypertension is unclear.
In this study, as a first step to approach this question and identify regulatory factors that play a role in the control of angiotensinogen gene transcription in the liver, we performed transient transfection assays using the mouse angiotensinogen promoter linked to chloramphenicol acetyltransferase (CAT) gene in hepatic HepG2 and other extrahepatic cell lines. The hepatoma cell line HepG2 cells have retained several properties ofhepatocytes (40) , express angiotensinogen mRNA ( 16) , and are considered to be a suitable model system to investigate the molecular mechanism of the angiotensinogen gene expression. We first demonstrated that the proximal promoter region from -96 to +22 was able to confer HepG2-specific transcriptional activity and identified two cis-acting elements that contributed to this specificity, angiotensinogen gene-activating element 2 (AGE2) (-96--52) and AGE3 (-6-+22). Electrophoretic mobility shift assay (EMSA) identified two nuclear factors, angiotensinogen gene-activating factor 2 (AGF2) and AGF3. AGF2 bound to AGE2 in HepG2-specific manner, whereas AGF3 interacted with AGE3 in all cell lines examined. DNase I footprint analysis indicated that the palindromic sequences were involved in AGF2 binding and that the exon 1 region was critical for AGF3 binding. Furthermore, substitution mutation analysis and heterologous promoter assay demonstrated that the cooperative interaction between these proximal and core promoter elements was essential for transcriptional activation of the angiotensinogen gene.
Methods
Cell culture. Hepatoma. HepG2 cells, cervical carcinoma HeLa cells, and glioblastoma T98G cells were maintained in MEM containing 10% FBS, 2 mM L-glutamine, 100 IU/ml penicillin, and 100,ug/ml streptomycin. Embryonic fibroblast NIH3T3 cells were cultured in DME supplemented with 10% FBS, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 Mg/ml streptomycin. These cell lines were kept in 5% CO2/95% air at 37°C and were passed twice in a week after trypsin-EDTA detachment.
Plasmid constructions. Genomic DNA cloning was performed from C57BL/6 mouse liver as described previously (20) . The angiotensinogen promoter-CAT hybrid genes were constructed as follows: Ag501, Ag399, Agl38, Ag96, Ag7O, Ag51, and Ag6 contain 523-bp (-501-+22) HinPI, 421-bp (-399-+22) PvuII/HinPI, 160-bp (-138-+22) HaeIII/HinPI, 118-bp (-96-+22) Sau3AI/HinPI, 92-bp (-70-+22) RsaI/HinPI, 73-bp (-51-+22) Sau3AI/HinPI, and 28-bp (-6-+22) MvaI/HinPI fragments, respectively, and these DNA fragments were subcloned into the BglII/HindIII sites of pUCSVOCAT (41) .
A competitive plasmid (pC-AGE3) contained six tandem copies of the 28-bp (-6-+22) MvaI/HinPI fragment inserted into the SmaI site of pUC 19. Site-directed mutagenesis. The Agl 38 hybrid gene was used as a template to construct mutations in AGE2 or AGE3 by oligonucleotidedirected mutagenesis (42) . The sequences of the oligonucleotide used to create AGEA2 were 5'-CCCCAGCTGAGGTlTTAGAGTA-GCCCA-3', while those for AGEA3 were 5'-CAGGGGATGTTGATGCGAGCCTAGGTrG-3'. Once the site-directed mutations (underlined) were obtained and confirmed by sequencing, the altered 160-bp (-138-+22) (-138) , respectively, to generate probes suitable for DNase I footprinting. After gel purification, the probe (-20,000 cpm) was incubated with nuclear extracts in a 50-Ml reaction volume containing 12 mM Hepes, pH 7.9,60 mM KCI, 4mM MgCl2, 0.1 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, 10% glycerol, and 1 Mg of double-stranded poly(dI-dC). The mixture was incubated for 30 min on ice, followed by 1 min at room temperature by the addition of 50 Ml of a solution containing 12 mM Hepes, pH 7.9,5 mM CaCl2, 5 mM MgCl2, and 5-250 ng of DNase I. The reaction was stopped by the addition of 100 Ml of 12 mM Hepes, pH 7.9, 0.6 M sodium acetate, pH 7, 0.5% SDS, 0.1 mM EDTA, and 20 Mg of transfer RNA (tRNA). The DNA was extracted with phenol-chloroform (1:1, vol/vol), and was precipitated with 2.5 vol of ethanol before electrophoresis on a 6% polyacrylamide/8 M urea sequencing gel. To define the position of the protected region, G + A sequence ladders were prepared (49) .
Results
Angiotensinogen proximal promoter directs transcription in HepG2-specific manner. We previously demonstrated that HepG2 cells derived from differentiated hepatoma expressed angiotensinogen mRNA, and no detectable levels of angiotensinogen mRNA were found in extrahepatic HeLa, T98G, and NIH3T3 cells by Northern blot analysis (18, 50). To define DNA sequences responsible for specific transcription in the angiotensinogen promoter in HepG2 cells, a 523-bp HinPI fragment of the gene containing the 501-bp 5'-flanking region, the transcriptional start site, and the 22-bp exon 1 at positions -501-+22 was inserted to the BglII/HindIII sites of pUCSVOCAT in the sense orientation with respect to the CAT gene (Ag501), and a series of 5'-deletion mutants extending from -501 to -6 were constructed and tested for their ability to promote transcription (Fig. 1 ). These chimeric constructs were transiently introduced into HepG2, HeLa, T98G, and NIH3T3 cells. The promoterless plasmid pUCSVOCAT (SVO) was used as a background reference, and pUCSV3CAT (SV3) was used as a positive control including the SV40 enhancerpromoter region (41) . All results were corrected for variations in transfection efficiency by reference to pUCSV3CAT.
In HepG2 cells, Ag501 was able to direct CAT activity to a significant level, and deletion of the promoter to position -96 (Ag96) resulted in a slight increase (1.8±0.4-fold) in CAT expression relative to the undeleted construct, Ag5O 1. Deletion to position -70 (Ag7O) and -51 (Ag5 1), however, reduced the promoter-CAT hybrid gene expression to 28±4.2 and 8.5±1.8% ofAg96, respectively. Further deletion up to position -6 (Ag6) decreased CAT activity almost to the background level demonstrated in the negative control, pUCSVOCAT. These results indicate that the proximal promoter region from -96 to +22 (Ag96) is sufficient to confer efficient CAT expression in HepG2 cells, and suggest that the proximal element from -96 to -52 (AGE2) is important for high level CAT activity in these cells and that the basal promoter sequences from -51 to +22 can still mediate minimal promoter activity in HepG2 cells, although the level of CAT activity is low.
None of the deletion mutants, on the other hand, were expressed upon transfection into HeLa, T98G, and NIH3T3 cells. This complete inactivity in these nonhepatoma cell lines was not because ofa lower transfection efficiency, since expression directed by the positive control pUCSV3CAT was almost at the same level in these cells as in HepG2 cells.
AGE2, the proximal element (-96--52), binding to HepG2-specific factor is important for efficient transcriptional activity ofangiotensinogen promoter. The 5'-deletion analysis suggested that the sequences between -96 and -52 (AGE2) were important for the high level CAT expression in HepG2 cells. To identify nuclear factors binding to this region, we performed EMSA using the end-labeled angiotensinogen promoter fragment from -96 to -52 (AGE2) as the probe. Nuclear extracts were prepared from HepG2, HeLa, T98G, and NIH3T3 cells, and from mouse liver. Incubation ofAGE2 with either HepG2 or liver nuclear extract produced a single retarded complex ( Fig. 2 A, arrowhead), which represented a sequence-specific interaction between AGE2 and nuclear factors in the extracts since these were competed out with 100-fold molar excess ofthe unlabeled AGE2. DNA fragment from -96 to +22, including both AGE2 (-96--52) and AGE3 (-6-+22), also competed for this binding with the liver nuclear extract, although sequences from -51 to +22, which contained AGE3 but not AGE2, failed to compete (Fig. 2 A) . In addition, a high molecular weight band in the liver extract lanes was observed at the top of the gel. This formation could be partially competed with 100-fold molar excess of the unlabeled AGE2. However, this binding could not be competed out completely by 500-fold molar excess ofthe unlabeled AGE2 (data not shown), and a promoter DNA fragment from -96 to +22, which contained the AGE2 and its downstream sequences through the exon 1 region, did not compete for this high molecular weight band (Fig. 2 A) . Thus, we considered that this band formation was due to nonspecific binding. On the other hand, nuclear extracts from HeLa, T98G, and NIH3T3 cells were not able to form DNA-protein complex with this element (Fig. 2 A) . These results indicate that the AGE2-binding activity is HepG2 specific and is not detectable in other extrahepatic cell lines. Furthermore, double-stranded oligonucleotides containing the consensus binding sequences for C/EBP, HNF-1, and Sp-1 failed to compete with this AGE2-binding activity (Fig. 2 A) , and oligonucleotides with binding motif for neither NF-1, AP-1, nor CRE competed with the binding (data not shown).
DNase I footprint analysis was performed to confirm the recognition site of this AGE2-binding factor (AGF2). A labeled DNA fragment from -399 to +22 was incubated with liver nuclear extracts followed by DNase I digestion. Fig. 2 Fig. 3 A) . The resulting AGEA2 was used for electrophoretic shift competition assay and transient transfection assay to assess the functional significance of AGF2 in the context of angiotensinogen promoter. As shown in Fig. 3 A, nonlabeled AGE2 competed effectively for the complex formation, whereas AGEL\2 containing the 8-bp mutations in the palindrome did not compete at all. The angiotensinogen promoter-CAT chimeric gene with this mutated AGEA2 (AgI38-A2) was then transiently transfected into HepG2 cells and assayed for induction ofCAT activity (Fig. 3 B) . The mutation of the palindromic sequences in AGE2 resulted in a substantial reduction in the level of CAT 38 . These results indicate that AGE2, especially the palindromic sequence from -76 to -65, is important for high level expression in HepG2 cells and that the activator property of AGE2 is dependent on nuclear factor (AGF2)-binding to the element in the angiotensinogen promoter context. AGE3, the core element (-6 to +22), binding to ubiquitous factor is necessary for the transcriptional activity ofangiotensinogen promoter. To identify nuclear factors binding to the minimal promoter sequences (-51 to +22), we carried out EMSA with this region as the probe and used fragments AGE2 (-96 to -52), A (-51 to +4), and AGE3 (-6 to +22), spanning different regions of the proximal promoter, for competition experiments (Fig. 4) . A specific shifted complex was observed with nuclear extracts from liver, HepG2, and extrahepatic cell lines examined (Fig. 4 A) . In the extracts from mouse liver, AGE3 competed for the formation of the complex, although fragment A containing the TATA box consensus sequence (TATAAA) and AGE2 was unable to compete with this binding. Similar results were obtained by using the 28-bp double-stranded DNA probe spanning -6 to +22 bp (AGE3) of the angiotensinogen promoter. A single specific band, which was competed by the unlabeled AGE3, was observed with nuclear extracts from mouse liver, HepG2, and other extrahepatic cell lines (Fig. 5 A) . These results demonstrated that a ubiquitously expressed nuclear factor (AGF3) binds to the core promoter region from -6 to +22 (AGE3).
DNase I footprint analysis using nuclear extracts from mouse liver showed a region of DNase I protection from -1 to + 14 in AGE3 (Fig. 5 B, hatched box) . The basal promoter elements around the TATA box (position -33 to -19) and its downstream region (position -16 to -3) were also protected from the digestion with DNase I (Fig. 5 B, open boxes) containing the TATA elements and the transcriptional start sites were used for electrophoretic shift competition assay (Fig.  6) . All ofthe promoter fragments tested failed to compete effectively for binding to AGE3. Furthermore, oligonucleotide with consensus binding motif for either C/EBP, HNF-1, Sp-l, NF-1, AP-1, or CRE could not compete with this binding (data not shown).
To evaluate the functional significance of AGE3 in HepG2-specific angiotensinogen promoter activity, we first assayed the effect of a mutation that disrupted nuclear factors binding to AGE3. As shown in Fig. 7 A, the DNA-protein complex formed by the AGE3-binding activity could be competed out by nonlabeled AGE3. However, the DNA fragment that contains substitution mutations in AGE3 of the exon 1 region (Fig. 7 A, AGEA3) was not able to compete for this binding. In transiently transfected HepG2 cells (Fig. 7 B) , the angiotensinogen promoter-CAT hybrid gene with this mutated AGE3 (Agl38-A3) gave the greatly reduced promoter activity (14±3.2% of the level with the native Agl38 construct). We next performed in vivo competition experiments to confirm the functional role ofAGE3 as a positive regulator. Six tandem copies ofAGE3 were inserted into the pUC19 plasmid. This plasmid, named pG-AGE3, was cotransfected with Ag5O 1 into HepG2 cells, and the CAT activities were analyzed (Fig. 8) . The amount of transfected DNA was normalized by pUC19 to 10 pg. The results obtained in this experiment
showed that the CAT activity decreases with increasing amounts of pC-AGE3. Therefore, these functional assays suggest that the core element overlapping the exon 1 region from +3 to + 14 in AGE3 is important as the recognition sequences for AGF3, and that AGE3 could, at least in part, support HepG2-specific promoter activity ofthe angiotensinogen gene.
Combination ofAGE2 andAGE3 confers synergistic activation on a heterologous promoter. To 
Discussion
In the classical endocrine RAS, the primary source of plasma angiotensinogen is the liver, and the regulation of hepatic angiotensinogen synthesis has been investigated ( 16, 17) . However, the basal transcriptional mechanism of the angiotensinogen gene in hepatocytes is not completely understood. In this study, we show that the cell type-specific activation ofthis gene transcription results from the cooperative interaction ofa proximal promoter element (AGE2) with a novel cis-acting element named AGE3 that resides directly around the transcriptional start site in the core promoter region. This conclusion is based on the following evidence. First, a transient transfection study indicates that the proximal promoter region from -96 to +22 of the angiotensinogen gene is sufficient to confer the cell type specificity on CAT reporter gene expression. Second, EMSA revealed that HepG2-specific AGF2 and ubiquitous AGF3 bind to AGE2 and AGE3, respectively. Third, experiments designed to test the involvement of these two elements in the promoter activity demonstrate that a synergistic interaction ofAGE2 and AGE3 contributes to HepG2-specific expression of the angiotensinogen promoter. In EMSA, HepG2 and liver nuclear extracts produced a specific retarded complex with AGE2 due to the binding of AGF2, whereas the nuclear extracts from HeLa, T98G, and NIH3T3 cells lacked detectable binding activity. Inspection of the DNA sequence of this element reveals a G-C rich 5'-left arm region and a perfect 12-bp palindrome (CTCTGTACA-GAG; -76 to -65) in the center region. The G-C box sequences, one ofthe most common regulatory DNA elements of eukaryotic genes, are often recognized by Sp-1 transcription factor ( 53 ) . Sp 1 binds to the G-C rich sequences within a few hundred base pairs upstream of the transcriptional start sites and activates transcription of genes encoding housekeeping proteins such as H-ras (54), c-myb (55) , insulin receptor (56) , and dihydrofolate reductase (44) (58) . Given that AGF3 is important for determination of the magnitude of cell type-specific transcriptional activity by AGF2, an interesting question can be raised concerning the possible implication of TBP in AGF3 binding to AGE3, because this element is closely located to the TATA box (-30 to -25). In previous analyses regarding TATA-binding activity, variation has been observed in the extent to which the footprints cover the transcription initiation region (59, 60) , and a downstream initiation element is reported to be important for efficient TATA box binding and in vitro function of TFIID (61 ), in part because of its functional heterogeneity (62) and its multicomponent complexity (63) , but the TATA site itself is invariably recognized in such footprints. In this sense, the footprint-protected region (-33 to - 19) 
